About Luxsol™
Luxsol™ is one of the few treatments in the USA to be covered by a patent granted by the USPTO to treat Covid-19 virus and Influenza:
US Patent No. 11,000,545 on May 11, 2021
Luxsol™ is one of the few treatments in the USA to be covered by a patent granted by the USPTO to treat Covid-19 virus and Influenza:
US Patent No. 11,000,545 on May 11, 2021
What is Luxsol™? Luxsol™ is a suspension that is intended for use as a targeted treatment for respiratory illness associated with Covid-19 and influenza. It is not a pill or an injection. It is a spray through the mouth delivering drug directly to lungs using a nebulizer.
Side effects are unknown at this stage, as the drug has not entered human studies. However, based on human experience with Luxsol™ side effects are expected to be both rare and mild.
Luxsol™ was successfully tested in the treatment of Covid-19 in an In vitro study using Remdesivir as the positive control. Both drugs were equally effective killing the SARS-COV-2 virus.
Luxsol™ is one of the few treatments in the USA to be covered by a USPTO patent to treat Covid-19 virus and Influenza.
3V Medical Research Group developed Luxsol™ as a targeted therapeutic.